Trials / Completed
CompletedNCT01495741
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
An Observational Post-Authorization Safety Surveillance (PASS) Study of Sycrest® (Asenapine) Among Patients Aged 18 and Older Diagnosed With Bipolar Disorder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 42 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®). The occurrence of identified and potential clinically important risks will also be assessed.
Conditions
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2017-12-18
- Completion
- 2017-12-18
- First posted
- 2011-12-20
- Last updated
- 2022-02-04
Source: ClinicalTrials.gov record NCT01495741. Inclusion in this directory is not an endorsement.